Nadezhda Lyamina

Prof. Nadezhda Lyamina

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Open access
MSMichael Szarek
Michael Szarek
MBMarie Baccara-Dinet
Marie Baccara-Dinet
ABAndrzej J Budaj
Andrzej J Budaj
RDRafael Diaz
Rafael Diaz
CHCorinne Hanotin
Corinne Hanotin
MMMark A McClanahan
Mark A McClanahan
After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1·4-1·8 mmol/L with ezetimibe or statins reduces cardiovascular events in patients with an acute coronary syndrome and diabetes. However, the efficacy and safety of further reduction in LDL cholesterol with an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) after acute coronary syndrome is unknown. We aimed to explore this issue in a prespecified analysis of the ODYSSEY OUTCOMES trial of the PCSK9 inhibitor alirocumab, assessing its effects on cardiovascular outcomes by baseline glycaemic status, while also assessing its effects on glycaemic measures including risk of new-onset diabetes. ODYSSEY OUTCOMES was a randomised, double-blind, placebo-controlled trial, done at 1315 sites in 57 countries, that compared alirocumab with placebo in patients who had been admitted to hospital with an acute coronary syndrome (myocardial infarction or unstable angina) 1-12 months before randomisation and who had raised concentrations of atherogenic lipoproteins despite use of high-intensity statins. Patients were randomly assigned (1:1) to receive alirocumab or placebo every 2 weeks; randomisation was stratified by country and was done centrally with an interactive voice-response or web-response system. Alirocumab was titrated to target LDL cholesterol concentrations of 0·65-1·30 mmol/L. In this prespecified analysis, we investigated the effect of alirocumab on cardiovascular events by glycaemic status at baseline (diabetes, prediabetes, or normoglycaemia)-defined on the basis of patient history, review of medical records, or baseline HbA1c or fasting serum glucose-and risk of new-onset diabetes among those without diabetes at baseline. The primary endpoint was a composite of death from coronary heart disease, non-fatal myocardial infarction, fatal or non-fatal ischaemic stroke, or unstable angina requiring hospital admission. ODYSSEY OUTCOMES is registered with ClinicalTrials.gov, number NCT01663402. At study baseline, 5444 patients (28·8%) had diabetes, 8246 (43·6%) had prediabetes, and 5234 (27·7%) had normoglycaemia. There were no significant differences across glycaemic categories in median LDL cholesterol at baseline (2·20-2·28 mmol/L), after 4 months' treatment with alirocumab (0·80 mmol/L), or after 4 months' treatment with placebo (2·25-2·28 mmol/L). In the placebo group, the incidence of the primary endpoint over a median of 2·8 years was greater in patients with diabetes (16·4%) than in those with prediabetes (9·2%) or normoglycaemia (8·5%); hazard ratio (HR) for diabetes versus normoglycaemia 2·09 (95% CI 1·78-2·46, p<0·0001) and for diabetes versus prediabetes 1·90 (1·65-2·17, p<0·0001). Alirocumab resulted in similar relative reductions in the incidence of the primary endpoint in each glycaemic category, but a greater absolute reduction in the incidence of the primary endpoint in patients with diabetes (2·3%, 95% CI 0·4 to 4·2) than in those with prediabetes (1·2%, 0·0 to 2·4) or normoglycaemia (1·2%, -0·3 to 2·7; absolute risk reduction pinteraction=0·0019). Among patients without diabetes at baseline, 676 (10·1%) developed diabetes in the placebo group, compared with 648 (9·6%) in the alirocumab group; alirocumab did not increase the risk of new-onset diabetes (HR 1·00, 95% CI 0·89-1·11). HRs were 0·97 (95% CI 0·87-1·09) for patients with prediabetes and 1·30 (95% CI 0·93-1·81) for those with normoglycaemia (pinteraction=0·11). After a recent acute coronary syndrome, alirocumab treatment targeting an LDL cholesterol concentration of 0·65-1·30 mmol/L produced about twice the absolute reduction in cardiovascular events among patients with diabetes as in those without diabetes. Alirocumab treatment did not increase the risk of new-onset diabetes. Sanofi and Regeneron Pharmaceuticals.

1 November 2011 in Journal Of Hypertension
Verified
Journal Article
Closed access
NLNadezhda P. Lyamina
Nadezhda P. Lyamina
SLSvetlana Lyamina
Svetlana Lyamina
VSValery N. Senchiknin
Valery N. Senchiknin
RMRobert T. Mallet
Robert T. Mallet
HDH. Fred Downey
H. Fred Downey
EMEugenia Manukhina
Eugenia Manukhina
Objectives Insufficient production and/or increased decomposition of the potent endogenous vasodilator nitric oxide plays an important role in development and progression of arterial hypertension and its complications. One of the most effective means of stimulating endogenous nitric oxide synthesis is controlled adaptation to hypoxia. This study examined the effect of a 20-day, intermittent, normobaric intermittent hypoxia conditioning (IHC) program on blood pressure (BP) and nitric oxide production in patients with stage 1 arterial hypertension. Methods The IHC sessions consisted of four to 10 cycles of alternating 3-min hypoxia (10% FIO2) and 3-min room air breathing. BP was monitored for 24 h before and after IHC, and nitric oxide synthesis was evaluated by 24-h urinary excretion of the stable nitric oxide metabolites nitrate and nitrite. Results IHC increased nitric oxide synthesis and decreased BP in hypertensive patients to values similar to those of normotensive individuals. Significant inverse correlations were found between nitric oxide production and disease duration, SBP, and DBP. Moreover, IHC enhancement of nitric oxide synthesis was especially robust in patients with arterial hypertension of more than 5 years duration. The reduction in BP persisted for at least 3 months in 28 of 33 hypertensive patients. Conclusion IHC exerted a robust, persistent therapeutic effect and can be considered as an alternative, nonpharmacological treatment for patients with stage 1 arterial hypertension. The antihypertensive action of IHC is associated with normalization of nitric oxide production.

11 June 2021 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
MBMarina G. Bubnova
Marina G. Bubnova
ESE. V. Shlyakhto
E. V. Shlyakhto
DAD. M. Aronov
D. M. Aronov
ABA. S. Belevsky
A. S. Belevsky
MGM. Yu. Gerasimenko
M. Yu. Gerasimenko
VTV. A. Tutelian
V. A. Tutelian
The expert consensus of the Russian communities discusses the issues of comprehensive medical rehabilitation of patients with coronavirus disease 2019 (COVID-19). COVID-19 is a contagious infectious disease that can cause pulmonary, cardiac, motor, metabolic, neurocognitive and mental disorders, that is, multiple organ dysfunction. COVID-19 survivors, especially after a severe clinical course, face serious psychological and physical problems, posttraumatic stress, cognitive dysfunction, nutritional deficiencies and exacerbation of concomitant chronic diseases. Some patients, regardless of the COVID-19 severity, have a long clinical course of the disease (“chronic-COVID”, “long COVID”). There is evidence of post-acute COVID-19 syndrome. In this regard, patients after COVID-19 will need rehabilitation measures. The expert consensus of the Russian communities presents general principles, stages and aspects of medical rehabilitation after COVID-19, indications and contraindications for rehabilitation interventions. The paper includes recommendations on comprehensive cardiac and pulmonary rehabilitation, as well as specifics of rehabilitation care for different COVID-19 courses within the national three-stage rehabilitation system.

11 June 2021 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
OGOleg Glazachev
Oleg Glazachev
NLN. P. Lyamina
N. P. Lyamina
GSG. K. Spirina
G. K. Spirina
The review describes the experience in intermittent hypoxic conditioning protocols in rehabilitation programs for patients with cardiovascular diseases. Based on randomized controlled trials, the efficacy and safety of intermittent hypoxic conditioning in patients with cardiovascular disease, including those with multicomorbidity in clinical practice, have been analyzed. From a physiological and clinical standpoints, the review justifies the need for further controlled clinical trials on hypoxic conditioning with a longer follow-up period both to expand the clinical indications for this method and to develop optimal combinations with exercise within cardiac rehabilitation programs. Discovery of the key mechanisms of adaptation to oxygen concentration changes and further research on hypoxia physiology will expand the application of this method in clinical and rehabilitation medicine in cardiac patients.

1 January 2017 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
NLN. P. Lyamina
N. P. Lyamina
AНArray В. Наливаева
Array В. Наливаева
VSV. N. Senchikhin
V. N. Senchikhin
TLT. P. Lipchanskaya
T. P. Lipchanskaya
AЛArray П. Липчанская
Array П. Липчанская
МАСКИРОВАННАЯ АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ У ЛИЦ МОЛОДОГО ВОЗРАСТА: ВЫЯВЛЯЕМОСТЬ, ВЫРАЖЕННОСТЬ КАРДИОВАСКУЛЯРНЫХ ФАКТОРОВ РИСКА И ПРОГНОЗ С УЧЕТОМ ГЕНДЕРНЫХ РАЗЛИЧИЙ